GlassScriptPhysician profile
Julia A Clark
NPI 1093180473
$752.85
in general payments reported to CMS, 2019-2025
20 companies · $214 in 2025
The $214 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $43.66 · 2022: $251 · 2023: $134 · 2024: $110 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $443 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $442.97 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $98.99 | 2022 | |
| Abbvie INC. | $77.64 | 2023-2025 | |
| Glaxosmithkline, LLC. | $68.93 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Electromed, INC. | $62.49 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $61.99 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $61.90 | 2023-2025 | Tezspire, Fasenra |
| Ars Pharmaceuticals Operations, INC. | $41.86 | 2025 | Neffy |
| Genzyme Corporation | $39.17 | 2022-2025 | |
| Grifols USA, LLC | $38.78 | 2025 | Xembify |
| Merck Sharp & Dohme LLC | $32.85 | 2023 | Keytruda |
| Amgen INC. | $24.16 | 2025 | Tezspire |
| Motiva USA, LLC | $23.74 | 2025 | |
| Hikma Pharmaceuticals USA | $22.15 | 2023 | Ryaltris |
| Optinose US, INC. | $19.95 | 2024 | |
| Ani Pharmaceuticals, INC. | $16.36 | 2024 | Purified Cortrophin Gel |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $15.63 | 2021 | |
| Kaleo, INC. | $15.36 | 2022 | |
| Pfizer INC. | $15.27 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.59 | 2024 | Fruzaqla |
| Genentech USA, INC. | $2.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.